Filtered By:
Condition: Alcoholism
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 51477 results found since Jan 2013.
Extended-Release Naltrexone as Effective, Safe as Buprenorphine-Naloxone, Study Finds
Treatment with extended-release naltrexone appears to be as safe and effective as daily oral buprenorphine-naloxone in maintaining short-term abstinence from heroin and other illicit substances in newly detoxified individuals, according to astudy inJAMA Psychiatry. The findings were based on a 12-week, multicenter, outpatient, open-label trial conducted at five addiction clinics in Norway. After detoxification, 159 opioid-dependent adults (according toDSM-4) were randomly assigned to either daily oral flexible dose buprenorphine-naloxone (4 mg/d to 24 mg/d) or extended-release naltrexone hydrochloride (380 mg, adminis...
Source: Psychiatr News - October 24, 2017 Category: Psychiatry Tags: alcohol amphetamine buprenorphine-naloxone cannabis cocaine extended-release naltrexone JAMA Psychiatry Lars Tanum opioid dependence withdrawal Source Type: research
Monthly Buprenorphine May Improve OUD Patients ’ Sense of Well-Being, Satisfaction With Treatment
Astudy in theJournal of Substance Abuse Treatment has shown that treating patients with opioid use disorder (OUD) with monthly injections of extended-release buprenorphine may result in measurable improvements in patients ’ quality of life and sense of well-being. This represents a departure from standard research on OUD treatment, which largely focuses on how long patients remain in treatment and whether they abstain from illicit opioid use, according to the researchers.“Outcomes that are easily measurable during office visits can help clinicians assess life changes reflective of a person’s recovery—a lifestyle ch...
Source: Psychiatr News - November 22, 2019 Category: Psychiatry Tags: buprenorphine extended-release Journal of Substance Abuse Treatment patient satisfaction quality of life Walter Ling Well-Being Source Type: research
Long-Acting Buprenorphine Formulation May Reduce Cravings While Lowering Misuse Risks
This study was also supported by the National Institute on Drug Abuse National Center for Research Resources and the National Center for Advancing of Translational Sciences.To read more about this topic, see thePsychiatric News article “Tackling Opioid Overdose Epidemic Demands Multiple Approaches. ”(Image: iStock/Ca-ssis)For previous news alerts,click here.
Source: Psychiatr News - July 3, 2017 Category: Psychiatry Tags: buprenorphine CAM2308 hydromorphone JAMA Psychiatry opioid use disorder Sharon Walsh Source Type: research
Availability of buprenorphine on the Internet for purchase without a prescription
Conclusion: Twenty online pharmacies advertising buprenorphine formulations for sale without a prescription were identified. Prices varied widely between illicit pharmacies but were uniformly more expensive than legitimate pharmacies. Illicitly obtained buprenorphine formulations appear to be relatively inaccessible and at high cost on the Internet.
Source: Drug and Alcohol Dependence - May 5, 2013 Category: Addiction Authors: Marcus A. Bachhuber, Chinazo O. Cunningham Tags: Short Communications Source Type: research
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.
CONCLUSIONS: Buprenorphine is an effective medication in the maintenance treatment of heroin dependence, retaining people in treatment at any dose above 2 mg, and suppressing illicit opioid use (at doses 16 mg or greater) based on placebo-controlled trials.However, compared to methadone, buprenorphine retains fewer people when doses are flexibly delivered and at low fixed doses. If fixed medium or high doses are used, buprenorphine and methadone appear no different in effectiveness (retention in treatment and suppression of illicit opioid use); however, fixed doses are rarely used in clinical practice so the flexible dose ...
Source: Cochrane Database of Systematic Reviews - February 6, 2014 Category: Journals (General) Authors: Mattick RP, Breen C, Kimber J, Davoli M Tags: Cochrane Database Syst Rev Source Type: research
Creation of an algorithm for clinical decision support for treatment of opioid use disorder with buprenorphine in primary care
CONCLUSION: Creation of these tools is the necessary first step for implementation of MBC for the treatment of OUD with buprenorphine in primary care. Further work is needed to test the feasibility and acceptability of these tools. Trial Registration ClinicalTrials.gov; NCT04059016; 16 August 2019; retrospectively registered; https://clinicaltrials.gov/ct2/show/NCT04059016.PMID:33608060 | PMC:PMC7893913 | DOI:10.1186/s13722-021-00222-0
Source: Addiction Science and Clinical Practice - February 20, 2021 Category: Addiction Authors: Adriane M Dela Cruz Robrina Walker Ronny Pipes Sidarth Wakhlu Madhukar H Trivedi Source Type: research
Meta-analysis of primary care delivered buprenorphine treatment retention outcomes
Conclusions: While we only investigate BT through primary care, our findings indicate retention rates are equivalent to the rates reported in the specialty care literature. More work is needed to examine factors that may impact primary care delivered BT specifically and differentiate participants that may benefit from care delivered in specialty over primary care as well as the converse.PMID:37737714 | DOI:10.1080/00952990.2023.2251653
Source: The American Journal of Drug and Alcohol Abuse - September 22, 2023 Category: Addiction Authors: Robert L Cooper Ryan D Edgerton Julia Watson Nicholas Conley William A Agee Derek M Wilus Samuel A MacMaster Lisa Bell Parul Patel Amruta Godbole Cynthia Bass-Thomas Aramandla Ramesh Mohammad Tabatabai Source Type: research
Creation of an algorithm for clinical decision support for treatment of opioid use disorder with buprenorphine in primary care.
CONCLUSION: Creation of these tools is the necessary first step for implementation of MBC for the treatment of OUD with buprenorphine in primary care. Further work is needed to test the feasibility and acceptability of these tools. Trial Registration ClinicalTrials.gov; NCT04059016; 16 August 2019; retrospectively registered; https://clinicaltrials.gov/ct2/show/NCT04059016.
PMID: 33608060 [PubMed - as supplied by publisher]
Source: Addiction Science and Clinical Practice - February 19, 2021 Category: Addiction Authors: Dela Cruz AM, Walker R, Pipes R, Wakhlu S, Trivedi MH Tags: Addict Sci Clin Pract Source Type: research
Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use
CONCLUSIONS: PWH with OUD spend relatively little time receiving buprenorphine in their HIV primary care clinic. Concurrent cocaine use at buprenorphine initiation negatively impact time on buprenorphine.PMID:37660116 | PMC:PMC10474763 | DOI:10.1186/s13722-023-00408-8
Source: Addiction Science and Clinical Practice - September 2, 2023 Category: Addiction Authors: Jarratt D Pytell Anthony T Fojo Jeanne C Keruly LaQuita N Snow Oluwaseun Falade-Nwulia Richard D Moore Geetanjali Chander Catherine R Lesko Source Type: research
Transition from methadone to subcutaneous buprenorphine depot in patients with opioid use disorder in custodial setting - a case series
CONCLUSIONS: Transition of opioid users from methadone to buprenorphine depot is feasible and safe via 4 mg buprenorphine sublingual. This procedure may facilitate induction of buprenorphine depot formulations in patients treated with methadone.PMID:34407703 | DOI:10.1080/00952990.2021.1963757
Source: The American Journal of Drug and Alcohol Abuse - August 19, 2021 Category: Addiction Authors: Michael Soyka Gregor Gro ß Source Type: research
Changes in buprenorphine visits in frontier and remote locations: Effects of the SARS-CoV-2 pandemic
CONCLUSIONS: In an area of the country with low pre-existing access to buprenorphine treatment for opioid use disorder, increases in buprenorphine visits were found after the pandemic began. This was particularly true of females who reside in frontier areas. Pandemic-related changes may have reduced barriers to this critical treatment, especially among rural populations.PMID:37065774 | PMC:PMC10052936 | DOI:10.1016/j.dadr.2023.100155
Source: Rural Remote Health - April 17, 2023 Category: Rural Health Authors: Lisa M McFadden Source Type: research
Measuring time in buprenorphine treatment stages among people with HIV and opioid use disorder by retention definition and its association with cocaine and hazardous alcohol use
CONCLUSIONS: PWH with OUD spend relatively little time receiving buprenorphine in their HIV primary care clinic. Concurrent cocaine use at buprenorphine initiation negatively impact time on buprenorphine.PMID:37660116 | DOI:10.1186/s13722-023-00408-8
Source: Addiction Science and Clinical Practice - September 2, 2023 Category: Addiction Authors: Jarratt D Pytell Anthony T Fojo Jeanne C Keruly LaQuita N Snow Oluwaseun Falade-Nwulia Richard D Moore Geetanjali Chander Catherine R Lesko Source Type: research
